Marcus S. Noel
Experienced in Tissue Biopsy

Dr. Marcus S. Noel

Oncology | Hospital Medicine | Hematology Oncology
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
17 Years of Experience
Experienced in Tissue Biopsy
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marcus Noel is an Oncologist and a Hospital Medicine provider in Washington, Washington, D.c.. Dr. Noel has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in Tissue Biopsy. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, and Tissue Biopsy.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Tissue Biopsy.

Graduate Year
2008
Specialties
Oncology
Hospital Medicine
Hematology Oncology
Licenses
Hospitalist in NY
Hospital Affiliations
Medstar Georgetown University Hospital
Medstar Washington Hospital Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
Enrollment Status: Recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drugs: Glufosfamide, Fluorouracil
Study Phase: Phase 3
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Biological, Drug
Study Drugs: Eryaspase, FOLFIRINOX
Study Phase: Phase 1
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer: A Phase II Study
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer: A Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: April 28, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

34 Total Publications

A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer.
A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer.
Journal: NPJ precision oncology
Published: March 24, 2025
Similar Doctors
Distinguished in Tissue Biopsy
Dr. James H. Doroshow
Oncology
Distinguished in Tissue Biopsy
Dr. James H. Doroshow
Oncology
Bethesda, MD 
 (5.0 miles away)
301-496-4291
Languages Spoken:
English

James Doroshow is an Oncologist in Bethesda, Maryland. Dr. Doroshow is rated as a Distinguished provider by MediFind in Tissue Biopsy. His top areas of expertise are Alveolar Soft Part Sarcoma, Desmoid Tumor, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Tissue Biopsy.

Experienced in Tissue Biopsy
Dr. Joshua E. Reuss
Oncology | Hematology
Experienced in Tissue Biopsy
Dr. Joshua E. Reuss
Oncology | Hematology

Mgmc LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (0.1 miles away)
202-444-3700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Reuss is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Reuss is rated as a Distinguished provider by MediFind in Tissue Biopsy. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Pleuropulmonary Blastoma, and Tissue Biopsy.

Experienced in Tissue Biopsy
Dr. Reetu Mukherji
Hematology Oncology | Hematology | Oncology
Experienced in Tissue Biopsy
Dr. Reetu Mukherji
Hematology Oncology | Hematology | Oncology

Mgmc LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (0.1 miles away)
202-444-3700
Experience:
9+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Reetu Mukherji is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Mukherji has been practicing medicine for over 9 years and is rated as an Experienced provider by MediFind in Tissue Biopsy. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, Stomach Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Noel's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile